190 related articles for article (PubMed ID: 17023575)
1. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl).
Podar K; Raab MS; Zhang J; McMillin D; Breitkreutz I; Tai YT; Lin BK; Munshi N; Hideshima T; Chauhan D; Anderson KC
Blood; 2007 Feb; 109(4):1669-77. PubMed ID: 17023575
[TBL] [Abstract][Full Text] [Related]
2. The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines.
Neri A; Marmiroli S; Tassone P; Lombardi L; Nobili L; Verdelli D; Civallero M; Cosenza M; Bertacchini J; Federico M; De Pol A; Deliliers GL; Sacchi S
Leuk Lymphoma; 2008 Jul; 49(7):1374-83. PubMed ID: 18452078
[TBL] [Abstract][Full Text] [Related]
3. Protein kinase C beta in malignant pleural mesothelioma.
Faoro L; Loganathan S; Westerhoff M; Modi R; Husain AN; Tretiakova M; Seiwert T; Kindler HL; Vokes EE; Salgia R
Anticancer Drugs; 2008 Oct; 19(9):841-8. PubMed ID: 18765998
[TBL] [Abstract][Full Text] [Related]
4. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia.
Moreau AS; Jia X; Ngo HT; Leleu X; O'Sullivan G; Alsayed Y; Leontovich A; Podar K; Kutok J; Daley J; Lazo-Kallanian S; Hatjiharissi E; Raab MS; Xu L; Treon SP; Hideshima T; Anderson KC; Ghobrial IM
Blood; 2007 Jun; 109(11):4964-72. PubMed ID: 17284528
[TBL] [Abstract][Full Text] [Related]
5. Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines.
Rizvi MA; Ghias K; Davies KM; Ma C; Weinberg F; Munshi HG; Krett NL; Rosen ST
Mol Cancer Ther; 2006 Jul; 5(7):1783-9. PubMed ID: 16891464
[TBL] [Abstract][Full Text] [Related]
6. Protein kinase C-beta inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis.
Dudek AZ; Zwolak P; Jasinski P; Terai K; Gallus NJ; Ericson ME; Farassati F
Invest New Drugs; 2008 Feb; 26(1):13-24. PubMed ID: 17805485
[TBL] [Abstract][Full Text] [Related]
7. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts.
Graff JR; McNulty AM; Hanna KR; Konicek BW; Lynch RL; Bailey SN; Banks C; Capen A; Goode R; Lewis JE; Sams L; Huss KL; Campbell RM; Iversen PW; Neubauer BL; Brown TJ; Musib L; Geeganage S; Thornton D
Cancer Res; 2005 Aug; 65(16):7462-9. PubMed ID: 16103100
[TBL] [Abstract][Full Text] [Related]
8. Enzastaurin renders MCF-7 breast cancer cells sensitive to radiation through reversal of radiation-induced activation of protein kinase C.
Jasinski P; Terai K; Zwolak P; Dudek AZ
Eur J Cancer; 2008 Jun; 44(9):1315-22. PubMed ID: 18448327
[TBL] [Abstract][Full Text] [Related]
9. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor.
Green LJ; Marder P; Ray C; Cook CA; Jaken S; Musib LC; Herbst RS; Carducci M; Britten CD; Basche M; Eckhardt SG; Thornton D
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3408-15. PubMed ID: 16740765
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of protein kinase C sensitise multiple myeloma cells to common genotoxic drugs.
Baumann P; Armann J; Mandl-Weber S; Grün G; Oduncu F; Schmidmaier R
Eur J Haematol; 2008 Jan; 80(1):37-45. PubMed ID: 18028419
[TBL] [Abstract][Full Text] [Related]
12. Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression.
Verdelli D; Nobili L; Todoerti K; Intini D; Cosenza M; Civallero M; Bertacchini J; Deliliers GL; Sacchi S; Lombardi L; Neri A
Hematol Oncol; 2009 Mar; 27(1):23-30. PubMed ID: 18759374
[TBL] [Abstract][Full Text] [Related]
13. Novel therapies targeting the myeloma cell and its bone marrow microenvironment.
Hideshima T; Chauhan D; Podar K; Schlossman RL; Richardson P; Anderson KC
Semin Oncol; 2001 Dec; 28(6):607-12. PubMed ID: 11740818
[TBL] [Abstract][Full Text] [Related]
14. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
Tai YT; Fulciniti M; Hideshima T; Song W; Leiba M; Li XF; Rumizen M; Burger P; Morrison A; Podar K; Chauhan D; Tassone P; Richardson P; Munshi NC; Ghobrial IM; Anderson KC
Blood; 2007 Sep; 110(5):1656-63. PubMed ID: 17510321
[TBL] [Abstract][Full Text] [Related]
15. Enzastaurin (LY317615), a protein kinase C beta selective inhibitor, enhances antiangiogenic effect of radiation.
Willey CD; Xiao D; Tu T; Kim KW; Moretti L; Niermann KJ; Tawtawy MN; Quarles CC; Lu B
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1518-26. PubMed ID: 19906497
[TBL] [Abstract][Full Text] [Related]
16. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells.
Lee KW; Kim SG; Kim HP; Kwon E; You J; Choi HJ; Park JH; Kang BC; Im SA; Kim TY; Kim WH; Bang YJ
Cancer Res; 2008 Mar; 68(6):1916-26. PubMed ID: 18339873
[TBL] [Abstract][Full Text] [Related]
17. Targeting protein kinase C by Enzastaurin restrains proliferation and secretion in human pancreatic endocrine tumors.
Molè D; Gagliano T; Gentilin E; Tagliati F; Pasquali C; Ambrosio MR; Pansini G; Degli Uberti EC; Zatelli MC
Endocr Relat Cancer; 2011 Aug; 18(4):439-50. PubMed ID: 21606156
[TBL] [Abstract][Full Text] [Related]
18. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.
Gupta D; Treon SP; Shima Y; Hideshima T; Podar K; Tai YT; Lin B; Lentzsch S; Davies FE; Chauhan D; Schlossman RL; Richardson P; Ralph P; Wu L; Payvandi F; Muller G; Stirling DI; Anderson KC
Leukemia; 2001 Dec; 15(12):1950-61. PubMed ID: 11753617
[TBL] [Abstract][Full Text] [Related]
19. Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo.
Hamasaki M; Hideshima T; Tassone P; Neri P; Ishitsuka K; Yasui H; Shiraishi N; Raje N; Kumar S; Picker DH; Jacob GS; Richardson PG; Munshi NC; Anderson KC
Blood; 2005 Jun; 105(11):4470-6. PubMed ID: 15705788
[TBL] [Abstract][Full Text] [Related]
20. Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells.
Tekle C; Giovannetti E; Sigmond J; Graff JR; Smid K; Peters GJ
Br J Cancer; 2008 Sep; 99(5):750-9. PubMed ID: 18728666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
